Skip to main content
Aarti Pharmalabs Limited logo

Aarti Pharmalabs Limited — Investor Relations & Filings

Ticker · AARTIPHARM ISIN · INE0LRU01027 LEI · 335800TTAKRBNDK5P363 BSE.NS Manufacturing
Open in API
Filings indexed 246 across all filing types
Latest filing 2025-02-05 Regulatory Filings
Country IN India
Listing BSE.NS AARTIPHARM

About Aarti Pharmalabs Limited

https://www.aartipharmalabs.com/

Aarti Pharmalabs Limited is a manufacturer of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and xanthine derivatives. The company specializes in the development and production of complex chemistry-based products for the global pharmaceutical and generic drug industries. Its core portfolio includes APIs across diverse therapeutic areas such as oncology, cardiovascular, and anti-diabetics. Additionally, the company is a major producer of xanthines, including caffeine and theophylline. Aarti Pharmalabs offers comprehensive Contract Development and Manufacturing Organization (CDMO) services, leveraging its integrated research and development capabilities and large-scale manufacturing facilities. The organization maintains high regulatory standards, ensuring compliance with international quality benchmarks to serve a global clientele.

Recent filings

Filing Released Lang Actions
Dividend
Regulatory Filings
2025-02-05 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a formal notification addressed to stock exchanges about an upcoming earnings conference call scheduled to discuss the company's Q3 FY25 financial results. It includes details such as date, time, dial-in numbers, and management participants. The document does not contain any financial data or results itself, but rather serves as an invitation or intimation of the earnings call event. The document length is short (2487 characters), and it explicitly states it is an 'Intimation of Earnings Conference Call' under Regulation 30 of SEBI (LODR) Regulations 2015. Therefore, this is not the earnings release or the call transcript but an announcement about the call. According to the classification rules, such notifications are best classified as Regulatory Filings (RNS) because they are regulatory announcements that do not fit other categories and are not the report or transcript itself.
2025-01-28 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-01-28 English
Board Meeting — Financial Results/Dividend/Other business matters
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges notifying them of an upcoming Board Meeting scheduled for February 5, 2025. The purpose of the meeting is to consider and approve the audited financial results for the quarter and nine months ended December 31, 2024, and to declare an interim dividend if any. The letter references Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events including board meetings. The document does not contain the financial results themselves but is an announcement of the board meeting where such results will be approved. It also mentions the closure of the trading window in relation to the announcement. The document length is short (1815 characters) and it is clearly an intimation or announcement rather than the actual financial report or earnings release. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2025-01-28 English
Action(s) taken or orders passed
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the reopening of manufacturing activities at the company's plant following a regulatory closure and payment of environmental compensation. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) 2015 and provides operational updates. The document is short (1739 characters) and serves as a regulatory announcement about operational status and environmental compliance, not a financial report or detailed filing. It does not contain financial statements, audit information, or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance updates that do not fit other categories.
2025-01-18 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate issued under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming dematerialisation activities for the quarter ended December 31, 2024. It is addressed to stock exchanges and compliance departments, and it is a compliance certificate rather than a financial report or announcement of financial results. The document is short (3134 characters) and serves as a regulatory compliance filing rather than a report or announcement of voting results, management changes, or financial performance. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for compliance certificates and miscellaneous regulatory documents that do not fit other categories.
2025-01-10 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.